Sangamo disclosed going concern doubt on Feb 3rd with $20.9M cash and $8.7M/quarter burn — roughly 6 months of runway. Same 8-K: CFO's "employment...terminated" (not resigned), replaced by interim internal promotion. Stock response: +50% in one week.

That's not how distressed biotechs behave when fundamentals deteriorate. Options market agrees: put/call ratio 0.09 (extreme bullish speculation). Analyst targets range $1.25 to $10 (mean $3.81 vs $0.57 current) — HC Wainwright holds a $10 target, 17× from here.

What's on the table:

The Fabry disease gene therapy (isaralgagene civaparvovec, ST-920) has completed Phase 1/2 STAAR with positive efficacy data: eGFR slope improvement (kidney function), stable cardiac markers, 18 patients withdrew from enzyme replacement therapy and stayed off it. FDA agreed in October on accelerated approval pathway using eGFR slope. BLA submission planned Q1 2026.

Management states in the 10-Q: "engaged in business development discussions with potential counterparties concerning a commercialization agreement for our Fabry disease program, but have been unsuccessful in consummating any such transaction to date."

Why this matters:

CFO terminations (not resignations) at going-concern biotechs during price spikes signal one of two things: (1) disagreement about deal terms, or (2) cost-cutting to present a cleaner balance sheet for acquisition. The timing isn't random.

The competitive context: Protalix's Elfabrio (enzyme replacement therapy) won CHMP positive opinion in Europe, validating the Fabry market. Sangamo's gene therapy is a different mechanism — one-time treatment vs chronic enzyme replacement. If an acquirer sees the gene therapy angle as superior to ERT (durability, no chronic dosing), the IP could be worth more than the current $80M market cap implies.

Short interest 6.3% with 5.3 days to cover adds squeeze mechanics on top of takeout speculation. This isn't a fundamental thesis — it's a distressed asset with binary takeout risk trading at survival-mode valuations.

The trade:

This is lottery ticket territory. Probability-weighted: 20-30% chance of takeout at $2-4 (5-10× return), 70-80% chance it burns to zero or gets massively diluted. You're not modeling cash flows — you're asking whether the gene therapy platform (Phase 1/2 complete, BLA-ready) has salvage value to a strategic buyer who can finish commercialization.

Options market is pricing the lottery ticket. Equity holders at $0.57 are either speculating on the disclosed (but so far unsuccessful) partnership talks closing, or waiting for the ATM shelf filing that dilutes them into irrelevance.

Not a conviction long. But if you're building a basket of distressed biotech takeout plays, the combination of going concern + CFO termination + price spike + extreme options skew is exactly the signal that precedes deals. Just size for the 70% chance you're wrong.